Siham Ait Benichou

Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting DMPK Transcripts for the Treatment of Myotonic Dystrophy Type 1.

M. Boutjdir, J. Puymirat, F. Rigo, 2022, Human gene therapy.

Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1

M. Boutjdir, J. Puymirat, M. Chahine, 2022, International journal of molecular sciences.

Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1

J. Puymirat, F. Rigo, C. Bennett, 2022, Gene therapy.